Cancer
Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
Published in Healthcare Mergers, Acquisitions and Ventures Week, February 16th, 2008
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to test whether anemic patients with active cancer not receiving concurrent chemotherapy or radiotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, communicated to physicians through a 'Dear Healthcare...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- "Interest in fresh breath highest among 18-24 year olds" - Oral
Kimberly-Clark Launches DentaBurst(TM) Freshening Teeth Cleaners - 50 Million Pound Challenge
50 Million Pound Challenge Teams Up With Churches to Spread the 'Gospel of Healthy Living' - Abbey Spanier Rodd & Abrams, Llp
Abbey Spanier Rodd & Abrams, LLP Files Class Action Lawsuit on Behalf of Purchasers of American Dental Partners, Inc. Securities - Abbott
Abbott to Present at Merrill Lynch Healthcare Conference - Access Pharmaceuticals, Inc.
Access Pharmaceuticals Announces $2.7 Million New Equity - Acesis Inc.
Status: - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
